New York City (13 – 17 December 2019) – Xavant Technology (Pty) Ltd will be attending the PostGraduate Assembly in Anesthesiology (PGA), sponsored by the New York State Society of Anesthesiologists, Inc., in New York City from December 13th to 17th 2019. Xavant will be showcasing their latest generation line-up of products for anesthesia, including…
The Cost of Postoperative Respiratory Adverse Events Respiratory impairment following general anaesthesia can pose a significant problem. Adverse and critical respiratory events (AREs and CREs) have been responsible for increased morbidity and mortality. The main cause of AREs after surgery is related to the use of neuromuscular blockers (NMBAs) during general anaesthesia. The action of…
Xavant Technology Announces First Dual-Sensor Neuromuscular Patient Monitor The Stimpod NMS450X NMT monitor for Anesthesia first to feature both AMG and EMG modalities in one single, portable patient monitoring system. Pretoria, South Africa, October. 15, 2019 – Xavant Technology, a pioneer in neuromuscular monitoring and innovative neuromodulation modalities, announced an addition to the company’s…
Orlando, USA (19 – 23 October 2019) – Xavant Technology (Pty) Ltd will be exhibiting at the American Society of Anesthesiologists at the Orange County Convention Center in Orlando, USA from 19 to 23 October 2019. The company is expected to announce an important product update at the meeting while showcasing their latest objective NMT…
Hamburg, Germany, 13 – 14 December 2019 – Xavant Technology (Pty) Ltd and Promedia Medizintechnik will be exhibiting at the Norddeutsche Anästhesie-Tage at Hotel Grand Elysée Hamburg, Germany, from 13 – 14 December 2019. Visit the Promedia Medizintechnik booth for a demonstration of the Stimpod NMS450X TOF Monitor’s new features. You can learn more about…
Garmisch-Partenkirchen, Germany, 18 – 19 October 2019 – Xavant Technology (Pty) Ltd and Promedia Medizintechnik will be exhibiting at the 49th Bayerische Anästhesietage in Garmisch-Partenkirche, Germany, from 18 – 19 October 2019. Visit the Promedia Medizintechnik booth for a demonstration of the Stimpod NMS450X TOF Monitor’s new features. You can learn more about the Stimpod…
Why Quantitative NMT Monitoring is Critical in Surgical Patients and How Best to Do It Some sort of assessment of neuromuscular transmission (NMT) is necessary in surgical patients by clinicians and anesthetists to get a feel for the depth of anesthesia. This assessment can be done using simple yet subjective clinical parameters or through more…
Münster, Germany, 28 – 30 November 2019 – Xavant Technology (Pty) Ltd and Promedia Medizintechnik will be exhibiting at the 51st Münsteraner Anästhesie-Symposium in Münster, Germany from 28 – 30 November 2019. Visit the Promedia Medizintechnik booth for a demonstration of the Stimpod NMS450X TOF Monitor’s new features. You can learn more about the Stimpod…
Berlin, Germany, 19 – 21 September 2019 – Xavant Technology (Pty) Ltd and Promedia Medizintechnik will be exhibiting at the 21st Capital Congress of the Deutsche Gesellschaft für Anästhesiologie & Intensivmedizin in Berlin, Germany from 19 to 21 September 2019. Visit the Promedia Medizintechnik booth for a demonstration of the Stimpod NMS450X TOF Monitor’s new…
Vienna, Austria, 1 – 3 June 2019 – Xavant Technology (Pty) Ltd will be attending Euroanaesthesia, the European Anaesthesiology Congress in Vienna, Austria from 1 – 3 June. The company, a pioneering developer of Train of Four monitors (TOF Monitors), is set to reveal a brand new technology upgrade for its Stimpod NMS450X TOF Monitor.…
The Stimpod NMS450X+, equipped with two different modalities (AMG and EMG), empowers anaesthesiologists to achieve safer intraoperative control of patients’ neuromuscular blockade. The full case NMT Monitoring enables safe extubation and eliminate residual paralysis in any hospital setting, provider preference and surgery type. This advanced technology empowers clinicians to have a safer and more precise control over the neuromuscular blockade during surgery, aligning with the latest guideline-concordant recommendations for the monitoring of patients for residual paralysis following the administration of a neuromuscular reversal agent. The ASA and ESAIC strongly recommend the use of a quantitative neuromuscular blocking agent monitor in conjunction with neuromuscular blocking agents.
While reversal drugs like Sugammadex are commonly used for NMBA reversal, they are not a foolproof solution and residual paralysis remains a significant concern based on clinical evidence. By incorporating the Stimpod NMS450X+ into their practice, anaesthesiologists can proactively monitor the depth of neuromuscular blockade, significantly reducing the incidence of residual paralysis in patients. This contributes to improved patient outcomes and a safer post-operative recovery.
The Stimpod NMS450X+ offers a cost-effective solution in the OR, PACU and ICU. With its two modalities, AMG and EMG, the device provides flexibility in monitoring options. The only neuromuscular monitoring system available with both AMG and EMG enabling cost control at the point-of-care based on need and specific setting, allowing affordable standardisation across the entire hospital. Cost of Care model, enabling monitoring of all drug usage to ensure optimal use, thus saving on both paralytic and recovery agents. This cost-saving feature ensures efficient resource management without compromising patient safety.
AMG offers the most cost-effective option to implement with a reusable sensor and versatile patient setup options enabling neuromuscular transmission monitoring of the hand, toe or face.
EMG is ideally suited for neuromuscular monitoring of surgeries where tucked hands and arms are required, with optimised performance through a patented, skin-like electrode.
Residual neuromuscular blockade after anaesthesia has been linked to severe complications and adverse outcomes, including increased oxygen desaturation, postoperative pneumonia, airway obstruction, and reintubation. By utilizing the Stimpod NMS450X+ and effectively preventing residual NMB, clinicians can contribute to reduced LOS in hospitals and improve patient recovery rates.
Anaesthesiologists worldwide who have adopted the Stimpod NMS450X+ demonstrate their commitment to following the latest guidelines and best practices in anaesthesia. By incorporating a quantitative NMBA monitor into their practice, clinicians align themselves with the recommendations set forth by the ASA and ESAIC, promoting a higher standard of care and patient safety. By utilizing the Stimpod NMS450X+, anaesthesiologists are a testament to its effectiveness to improve patients outcomes and can contribute to the reduction of adverse events and enhance the recovery process for their patients.
